275 related articles for article (PubMed ID: 26336595)
1. Medical treatment update on pulmonary arterial hypertension.
Enderby CY; Burger C
Ther Adv Chronic Dis; 2015 Sep; 6(5):264-72. PubMed ID: 26336595
[TBL] [Abstract][Full Text] [Related]
2. Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Watanabe H
Eur Cardiol; 2018 Aug; 13(1):35-37. PubMed ID: 30310468
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the management of pulmonary arterial hypertension.
Tsai H; Sung YK; de Jesus Perez V
F1000Res; 2016; 5():2755. PubMed ID: 27990270
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
[TBL] [Abstract][Full Text] [Related]
5. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
Yao A
J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
Ghofrani HA; Grünig E; Jansa P; Langleben D; Rosenkranz S; Preston IR; Rahaghi F; Sood N; Busse D; Meier C; Humbert M
Pulm Circ; 2020; 10(3):2045894020942121. PubMed ID: 32728421
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.
Buckley MS; Berry AJ; Kazem NH; Patel SA; Librodo PA
Core Evid; 2014; 9():71-80. PubMed ID: 25018685
[TBL] [Abstract][Full Text] [Related]
9. An update on medical therapy for pulmonary arterial hypertension.
Wu Y; O'Callaghan DS; Humbert M
Curr Hypertens Rep; 2013 Dec; 15(6):614-22. PubMed ID: 24122306
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Radosevich J; Dutt M
Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
[TBL] [Abstract][Full Text] [Related]
11. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
12. Medical therapies for pulmonary arterial hypertension.
Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Arterial Hypertension: Pathophysiology and Treatment.
Lan NSH; Massam BD; Kulkarni SS; Lang CC
Diseases; 2018 May; 6(2):. PubMed ID: 29772649
[TBL] [Abstract][Full Text] [Related]
14. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
Seferian A; Simonneau G
Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
[TBL] [Abstract][Full Text] [Related]
15. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
16. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases.
Smukowska-Gorynia A; Gościniak W; Woźniak P; Iwańczyk S; Jaxa-Kwiatkowska K; Sławek-Szmyt S; Janus M; Paluszkiewicz J; Mularek-Kubzdela T
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765060
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment of HIV-associated pulmonary hypertension.
Chinello P; Petrosillo N
Expert Rev Clin Pharmacol; 2016; 9(5):715-25. PubMed ID: 26863919
[TBL] [Abstract][Full Text] [Related]
19. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
